莫沙必利

莫沙必利(英語:是一种消化道促动力药,选择性激动5-HT4受体,其主要代谢产物M1还具有5HT3受体的竞争性拮抗作用。[1]莫沙必利可以加速胃排空,促进全消化道的蠕动,用来治疗胃炎胃食管反流病功能性消化不良过敏性肠综合征[2][3][4][5]枸缘酸盐形式的莫沙必利,由大日本住友制药在1998年以加斯清为商品名上市销售。

莫沙必利
系统(IUPAC)命名名称
(RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}benzamide
临床数据
Drugs.com国际药品名称
给药途径口服
识别
CAS注册号112885-41-3  N
ATC代码None
PubChemCID 119584
IUPHAR/BPS242
ChemSpider106780 
UNIII8MFJ1C0BY 
KEGGD08236 
ChEMBLCHEMBL60889 
化学
化学式C21H25ClFN3O3
摩尔质量421.893 g/mol

參見

  • 蕈毒鹼拮抗劑(Muscarinic antagonist、蕈毒鹼性受體拮抗劑)

引用

  1. Tack, J.; Camilleri, M.; Chang, L.; Chey, WD.; Galligan, JJ.; Lacy, BE.; Müller-Lissner, S.; Quigley, EM.; Schuurkes, J. . Aliment Pharmacol Ther. Apr 2012, 35 (7): 745–67. PMID 22356640. doi:10.1111/j.1365-2036.2012.05011.x.
  2. Odaka T, Suzuki T, Seza A, Yamaguchi T, Saisho H. . Nippon Rinsho. August 2006, 64 (8): 1491–4. PMID 16898619 (日语).
  3. Curran MP, Robinson DM. . Drugs. 2008, 68 (7): 981–91. PMID 18457463. doi:10.2165/00003495-200868070-00007.
  4. Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, Omagari K, Takeshima F, Kohno S. Recent insights into digestive motility in functional dyspepsia. Journal of Gastroenterology. 2006 Nov;41(11):1025-40.
  5. Kato S, Morie T, Yoshida N. Synthesis and biological activities of metabolites of mosapride, a new gastroprokinetic agent.Chemical and Pharmaceutical Bulletin (Tokyo). 1995 Apr;43(4):699-702.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.